Takara Bio Europe adds a GMP-grade medium for MSC-derived EV production

Takara Bio Europe said on October 28, 2026 that it is launching a GMP grade of Cellartis MSC EV Wonder, a medium for producing extracellular vesicles (EVs) from mesenchymal stem cells (MSCs). The medium is chemically defined and xeno-free, so every component and its concentration is fixed. The research grade launched in September 2025. The company describes the GMP grade as an addition to the line for customers moving out of research and into clinical development and manufacturing. MSC-derived EVs are under study for regenerative medicine and for immune modulation.

The supplier is worth naming precisely. Takara Bio Europe is the European subsidiary of Japan's Takara Bio, so this raw material comes from inside a Japanese group. If your EV product is headed for Japan or for a Japanese development partner, that is the entity your incoming-material file and your questions about changes point to.

Taking bovine serum out keeps bovine vesicles out of the harvested fraction

Produce EVs in a medium without fetal bovine serum and the harvested fraction carries no bovine vesicles. Fetal bovine serum contains large amounts of bovine EVs to begin with. Culture in serum-containing medium and those vesicles land in the same fraction as the ones your cells released, in a form you cannot separate from them, with particle count and protein content both raised by the serum's share. In that state, purity and marker positivity are hard to read as values for the product. EV Wonder also leaves out phenol red. On the research-grade product page, the company describes the composition as low in background particles and easy to carry into downstream separation and analysis.

Before you compare grades, check whether the particle and purity numbers you are comparing were measured in serum-containing medium at all.

Moving from expansion to production without adapting the cells

According to the company, the medium shares its basal medium with the Cellartis MSC Xeno-Free Culture System used to expand MSCs, and an EV production supplement is combined with it. The company says no step is needed to adapt the cells to a new medium when you switch over to production. The research-grade user manual gives the procedure: at 65 to 85 percent confluence, wash with D-PBS (-/-), the version without calcium or magnesium, change to EV Wonder, and collect the supernatant five days later.

That does not make the switch free. Taking serum out of a medium changes the state of the cells, and both the amount of vesicles released and their composition move with it. When the medium changes, measure again on both sides, the MSCs and the vesicles.

A medium change that skips the adaptation step still needs the same re-measurement as one that does not.

What to verify again when research grade becomes GMP grade

Research-grade EV Wonder (Cat. # Y51000) is for research use only and is not intended for in vivo use in humans or animals. The European Commission's GMP guidelines for advanced therapy medicinal products (ATMPs) hold that raw materials should be of a quality appropriate for their intended use, and leave the judgment on which materials are critical, and the record of that judgment, with the manufacturer (EudraLex Volume 4, Part IV, sections 2.3.1 and 7.12 onward). Changing the grade does not move that work to the supplier. Quality at the outlet of your process is still yours to verify.

The comparison to run across the change is particle count, the ratio of particle count to protein, positivity for CD9, CD63 and CD81 along with the negative markers, and size distribution. On the supplier side, look at the test items on the certificate of analysis, the conditions under which the supplier notifies you of a change, and how supply is organized.

Takara Bio has a Japan-facing precedent worth asking about. For another GMP-grade product in the Cellartis line, the DEF-CS 500 GMP-grade basal medium for ES and iPS cells, the company states on that product page that it keeps the same composition as the research-grade medium, manufactures it in line with the PIC/S GMP guide, and has registered it in PMDA's Master File. Another point for anyone selling into Japan: animal and human material in media falls under Japan's Standard for Biological Ingredients, so a medium that contains none of it narrows what a Japanese customer asks you to document.

Ask the supplier whether the GMP grade of this medium is set up the same way, in writing, rather than reading the arrangement across from the DEF-CS precedent.

What has been added is an option at the raw material end, not a result. Whether the particle counts, purity and marker data you built up on the research grade land in the same range on the GMP grade is the check that sits between your current data set and clinical-scale manufacturing.